Oral Green Tea Extract for Small Cell Lung Cancer

Trial Title: Oral Green Tea Extract for Small Cell Lung Cancer

NCT ID: NCT01317953

Condition: Small Cell Lung Carcinoma

Conditions: Official terms:
Small Cell Lung Carcinoma
Epigallocatechin gallate

Study type: Expanded Access

Overall status: Available

Intervention:

Intervention type: Dietary Supplement
Intervention name: epigallocatechin gallate
Description: Starting dose green tea catechin extract "EGCG" 400 mg twice a day (BID) of EGCG (400 mg caps BID), second escalated dose 800 mg BID of EGCG (2x400 mg caps BID), third escalated dose 1200 mg BID of EGCG (3x400 mg),fourth escalated dose 1600 mg BID of EGCG (4x400 mg),and fifth escalated dose 2000 mg BID of EGCG (5x400 mg),

Other name: EGCG

Summary: The purpose of this study is to determine whether green tea extract is safe for extensive-stage small lung cancer who achieved objective tumor response after first-line therapy.

Detailed description: Small-cell lung cancer accounts for 13 to 15% of all lung cancer and more than 60 to 70% of patients present with extensive disease (ED). Although etoposide plus cisplatin (EP) regimen has been the mainstay of ED-SCLC treatment, median overall survival is about 9 months, with 5 to 10% surviving two years and only 1% of patients achieving a long-term disease-free survival. To improve this outcome further, various attempts have been made, which included dose intensification with stem cell supports, maintenance therapy, and also searches for a better chemotherapy regimen. Significant anticarcinogenic effects of green tea extract on various organs, such as skin, stomach, duodenum, colon, liver, pancreas, and lung in rodent models have been confirmed. Recent scientific investigations have identified the active chemical compounds in green tea designated tea polyphenols or catechins. Epigallocatechin-3-gallate (EGCG) is the major catechin in tea.An investigation about the effects of EGCG on human SCLC cells revealed that EGCG had similar anti-tumor effects on drug-sensitive (H69) and drug-resistant (H69VP) SCLC cells. Thus, the investigators conduct this phase I trial, the objectives of this trial were to study the side effects and best dose of of EGCG in treating patients with small-cell lung cancer who achieved objective tumor response after first-line therapy.

Criteria for eligibility:
Criteria:
Inclusion Criteria: - Confirmed diagnosis of small cell lung cancer - extensive-stage disease - Eastern Cooperative Oncology Group performance status (PS) of 0 to 2 - age18 years old - Adequate bone marrow reserves: neutrophil (ANC) count ≥ 1500 /mm^3, platelet count ≥ 100,000 /mm^3, hemoglobin ≥ 9 g/dl - Adequate renal function: serum creatinine ≤ 1.5 mg/dl and/or calculated creatinine clearance ≥ 60 ml/min - Adequate hepatic function: bilirubin level ≤ 1.5 x ULN, ASAT & ALST ≤ 1.5 x ULN - Signed written informed consent prior to study entry - According to Response Evaluation Criteria in Solid Tumors(RECIST), patients didn't progress after first-line chemotherapy Exclusion Criteria: - Any condition that would hamper informed consent or ability to comply with the study protocol - Participation in another research study in the last three months - Known malignancy at any site other than SCLC - Recent consumption of green tea (5 or more cups per day within one week of study enrollment) - Pregnant and lactating women - History of allergic reactions attributed to compounds of similar chemical or biologic composition to EGCG

Gender: All

Minimum age: 18 Years

Maximum age: 70 Years

Healthy volunteers: No

Locations:

Facility:
Name: Shan Dong cancer hospital and institute

Address:
City: Jinan
Zip: 250117
Country: China

Status: Available

Contact:
Last name: Xindong Sun, M.D.

Phone: 0086053167626141
Email: zhx87520052@163.com.cn

Contact backup:
Last name: Hanxi Zhao, M.D.

Phone: 0086053167626995
Email: 171459576@qq.com

Lead sponsor:
Agency: Shandong Cancer Hospital and Institute
Agency class: Other

Source: Shandong Cancer Hospital and Institute

Record processing date: ClinicalTrials.gov processed this data on November 12, 2024

Source: ClinicalTrials.gov page: https://clinicaltrials.gov/ct2/show/NCT01317953